| Date | Title | Description | |
|---|---|---|---|
| 26 Jun 2024 | On corporate transactions | ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives | Download | 
| 24 Jun 2024 | On business and financial situation | ROVI publishes the press release in relation to information and guidance on its strategic plan for expansion and growth | Download | 
| 08 May 2024 | On P&L | The Company releases the press release related to the first three months of 2024 financial results | Download | 
| 08 May 2024 | On P&L | The Company releases the first three months 2024 financial results presentation | Download | 
| 25 Apr 2024 | On business and financial situation | ROVI announces agreement to manufacture pre-filled syringes | Download | 
Pages
| Date | Title | Description | |
|---|---|---|---|
| 25 Feb 2025 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2024 annual report regarding remuneration of the members of the Board of Directors | Download | 
| 07 Jan 2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the fourth quarter of 2024 | Download | 
| 07 Nov 2024 | On P&L | A correction to the English version of a document is reported. | Download | 
| 03 Oct 2024 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2024 | Download | 
| 12 Sep 2024 | Other relevant information | The Company announces the registration in the Commercial Registry of the public deed of reduction of its share capital and the new share capital figure. | Download | 
Pages
| Date | Title | Description | |
|---|---|---|---|
| 26 Feb 2019 | Información sobre resultados | ROVI releases the presentation related to the full year 2018 results | Download | 
| 26 Feb 2019 | Información sobre resultados | ROVI releases the press release related to the full year 2018 results | Download | 
| 15 Feb 2019 | Others on business performance and financial information | ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets | Download | 
| 09 Jan 2019 | Others on business performance and financial information | ROVI informs about the adquisition of Falithrom® for the German market | Download | 
| 08 Jan 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the fourth quarter of 2018 | Download | 







